496 related articles for article (PubMed ID: 6543037)
1. Inherited fibrinolytic disorder due to an enhanced plasminogen activator level.
Aznar J; Estellés A; Vila V; Regañón E; España F; Villa P
Thromb Haemost; 1984 Oct; 52(2):196-200. PubMed ID: 6543037
[TBL] [Abstract][Full Text] [Related]
2. Increased fibrinolytic activity during use of oral contraceptives is counteracted by an enhanced factor XI-independent down regulation of fibrinolysis: a randomized cross-over study of two low-dose oral contraceptives.
Meijers JC; Middeldorp S; Tekelenburg W; van den Ende AE; Tans G; Prins MH; Rosing J; Büller HR; Bouma BN
Thromb Haemost; 2000 Jul; 84(1):9-14. PubMed ID: 10928462
[TBL] [Abstract][Full Text] [Related]
3. In vitro clot lysis as a potential indicator of thrombus resistance to fibrinolysis--study in healthy subjects and correlation with blood fibrinolytic parameters.
Colucci M; Scopece S; Gelato AV; Dimonte D; Semeraro N
Thromb Haemost; 1997 Apr; 77(4):725-9. PubMed ID: 9134650
[TBL] [Abstract][Full Text] [Related]
4. Comparison of the relative fibrinogenolytic, fibrinolytic and thrombolytic properties of tissue plasminogen activator and urokinase in vitro.
Matsuo O; Rijken DC; Collen D
Thromb Haemost; 1981 Jun; 45(3):225-9. PubMed ID: 7025339
[TBL] [Abstract][Full Text] [Related]
5. Plasminogen, plasminogen activator, and platelets in the regulation of clot lysis. Reconstitution and patient studies.
Carroll RC; Radcliffe RD; Taylor FB; Gerrard JM
J Lab Clin Med; 1982 Dec; 100(6):986-96. PubMed ID: 6890569
[TBL] [Abstract][Full Text] [Related]
6. [Fibrinolytic system in patients with nephrotic syndrome].
Andreenko GV; Poliantseva LR; Smirnova TA; Podorol'skaia LV
Ter Arkh; 1976; 40(2):89-99. PubMed ID: 135367
[No Abstract] [Full Text] [Related]
7. Intravascular and peritoneal coagulation and fibrinolysis in horses with acute gastrointestinal tract diseases.
Collatos C; Barton MH; Prasse KW; Moore JN
J Am Vet Med Assoc; 1995 Aug; 207(4):465-70. PubMed ID: 7591947
[TBL] [Abstract][Full Text] [Related]
8. Retinoic acid enhances fibrinolytic activity in-vivo by enhancing tissue type plasminogen activator (t-PA) activity and inhibits venous thrombosis.
van Giezen JJ; Boon GI; Jansen JW; Bouma BN
Thromb Haemost; 1993 Apr; 69(4):381-6. PubMed ID: 8497851
[TBL] [Abstract][Full Text] [Related]
9. [Fibrinolytic system in patients with myocardial infarction and other coronary disease risk factors].
Moreno JA; Gálvez MM; Cornudella R; Angós JA; Romero MS; Gutiérrez M
Sangre (Barc); 1994 Apr; 39(2):111-6. PubMed ID: 8059288
[TBL] [Abstract][Full Text] [Related]
10. Familial high plasminogen activator inhibitor with hypofibrinolysis, a new pathophysiologic cause of osteonecrosis?
Glueck CJ; Glueck HI; Mieczkowski L; Tracy T; Speirs J; Stroop D
Thromb Haemost; 1993 May; 69(5):460-5. PubMed ID: 8322268
[TBL] [Abstract][Full Text] [Related]
11. Dysfibrinogenemia (fibrinogen Dusard) associated with impaired fibrin-enhanced plasminogen activation.
Lijnen HR; Soria J; Soria C; Collen D; Caen JP
Thromb Haemost; 1984 Feb; 51(1):108-9. PubMed ID: 6539000
[TBL] [Abstract][Full Text] [Related]
12. [Effect of a single administration of plasminogen tissue activator on the state of the fibrinolytic system of rat blood].
Andreenko GV; Shimonaeva EE; Liutova LV; Serebriakova TN
Vopr Med Khim; 1981; 27(1):77-80. PubMed ID: 7193381
[TBL] [Abstract][Full Text] [Related]
13. Plasminogen activators (t-PA and u-PA) and plasminogen activators inhibitors (PAI-1 and PAI-2) in some myeloproliferative syndromes.
Rość D; Kremplewska-Nalezyta E; Gadomska G; Zastawna E; Michalski A; Drewniak W
Med Sci Monit; 2000; 6(4):684-91. PubMed ID: 11208392
[TBL] [Abstract][Full Text] [Related]
14. Plasma fibrinolytic activity following oral anabolic steroid therapy.
Walker ID; Davidson JF; Young P; Conkie JA
Thromb Diath Haemorrh; 1975 Sep; 34(1):236-45. PubMed ID: 1103357
[TBL] [Abstract][Full Text] [Related]
15. Fibrinolysis in patients with acute ischaemic heart disease. With particular reference to systemic effects of tissue-type plasminogen activator treatment on fibrinolysis, coagulation and complement pathways.
Munkvad S
Dan Med Bull; 1993 Sep; 40(4):383-408. PubMed ID: 8222763
[TBL] [Abstract][Full Text] [Related]
16. Fibrinogen Nijmegen: congenital dysfibrinogenemia associated with impaired t-PA mediated plasminogen activation and decreased binding of t-PA.
Engesser L; Koopman J; de Munk G; Haverkate F; Nováková I; Verheijen JH; Briët E; Brommer EJ
Thromb Haemost; 1988 Aug; 60(1):113-20. PubMed ID: 3142089
[TBL] [Abstract][Full Text] [Related]
17. Changes in coagulation and tissue plasminogen activator after the treatment of cerebral infarction with lumbrokinase.
Jin L; Jin H; Zhang G; Xu G
Clin Hemorheol Microcirc; 2000; 23(2-4):213-8. PubMed ID: 11321442
[TBL] [Abstract][Full Text] [Related]
18. Platelet hyperactivation in patients with essential thrombocythemia is not associated with vascular endothelial cell damage as judged by the level of plasma thrombomodulin, protein S, PAI-1, t-PA and vWF.
Bellucci S; Ignatova E; Jaillet N; Boffa MC
Thromb Haemost; 1993 Nov; 70(5):736-42. PubMed ID: 8128427
[TBL] [Abstract][Full Text] [Related]
19. [Tissue type plasminogen activator and its inhibition in blood of patients operated on for prostatic carcinoma].
Iwan-Zietek I; Zietek Z; Kotschy M; Rość D; Tyloch F
Pol Tyg Lek; 1996 Feb; 51(6-9):91-3. PubMed ID: 8756741
[TBL] [Abstract][Full Text] [Related]
20. Highly stable plasminogen activator inhibitor type one (VLHL PAI-1) protects fibrin clots from tissue plasminogen activator-mediated fibrinolysis.
Jankun J; Aleem AM; Selman SH; Skrzypczak-Jankun E; Lysiak-Szydlowska W; Grafos N; Fryer HJ; Greenfield RS
Int J Mol Med; 2007 Nov; 20(5):683-7. PubMed ID: 17912461
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
